Advertisement

The effect of probiotics on the incidence of Clostridioides difficile: Retrospective cohort analysis

Published:October 10, 2019DOI:https://doi.org/10.1016/j.ajic.2019.07.026

      Highlights

      • Those on probiotics had a higher risk of Clostridioides difficile infection (CDI).
      • Use of proton pump inhibitors or histamine 2 receptor antagonists increased CDI.
      • Sex and age did not have a significant impact on incidence of CDI.
      • Time of probiotic initiation to antibiotic administration had no impact on CDI.
      • Number of concurrent antibiotics significantly increased risk for incidence of CDI.

      Background

      Conflicting evidence exists regarding probiotics and the incidence of Clostridioides difficile infection (CDI). This study evaluates whether probiotics are efficacious for CDI prophylaxis in patients receiving antibiotics.

      Methods

      A retrospective cohort analysis of patients admitted to NYU Winthrop Hospital who received at least 1 dose of antibiotics considered high risk of inducing CDI. Patients were grouped according to probiotic use; association between probiotic use and incident CDI was examined. A model for incident CDI adjusting for known CDI risk factors was estimated.

      Results

      Of 3,267 patients, 4.6% had CDI within 12 weeks of antibiotics initiation. A total of 5.1% received probiotics within 24 hours of initiation, and 6.6% initiated probiotics during the 12-week follow-up. Of those taking probiotics within 24 hours of antibiotics, 9.6% had CDI, and of those not taking probiotics 4.2% had CDI (relative risk, 2.3; 95% confidence interval, 1.4, 3.7). In time-dependent Cox models accounting for probiotic initiation and adjusting for potential confounders, a positive association between probiotics and CDI remained significant (hazard ratio, 2.7; P < .001).

      Discussion

      Patients who received antibiotics with concurrent probiotics were more likely to have an incident of CDI compared with those who did not receive probiotics. Additional risk factors were histamine 2 receptor antagonists, proton pump inhibitors, and administration of multiple antibiotics simultaneously.

      Conclusions

      The present study, because of its large population and inclusion of multiple variables playing a role in CDI, serves as a valuable resource when considering efficacy of probiotics as CDI prophylaxis.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lawson PA
        • Citron DM
        • Tyrrell KL
        • Finegold SM
        Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938.
        Anaerobe. 2016; 40: 95-99
        • Napolitano LM
        • Edmiston Jr, CE
        Clostridium difficile disease: diagnosis, pathogenesis, and treatment update.
        Surgery. 2017; 162: 325-348
        • Yi SH
        • Jernigan JA
        • Mcdonald LC
        Prevalence of probiotic use among inpatients: a descriptive study of 145 US hospitals.
        Am J Infect Control. 2016; 44: 548-553
        • Mcdonald LC
        • Gerding DN
        • Johnson S
        • Bakken JS
        • Carroll KC
        • Coffin SE
        • et al.
        Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
        Clin Infect Dis. 2018; 66 (e1-48)
        • Goldstein EJC
        • Johnson SJ
        • Maziade PJ
        • Evans CT
        • Sniffen JC
        • Millette M
        • et al.
        Probiotics and prevention of Clostridium difficile infection.
        Anaerobe. 2017; 45: 114-119
        • Allen SJ
        • Wareham K
        • Wang D
        • Bradley C
        • Hutchings H
        • Harris W
        • et al.
        Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
        Lancet. 2013; 382: 1249-1257
        • Goldenberg JZ
        • Yap C
        • Lytvyn L
        • Lo CKF
        • Beardsley J
        • Mertz D
        • et al.
        Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children.
        Cochrane Database Syst Rev. 2017; 12CD006095
        • Shen NT
        • Maw A
        • Tmanova LL
        • Pino A
        • Ancy K
        • Crawford CV
        • et al.
        Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis.
        Gastroenterology. 2017; 152 (1889-900.e9)
        • Lau CS
        • Chamberlain RS
        Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.
        Int J Gen Med. 2016; 9: 27-37
        • Haran JP
        • Hayward G
        • Skinner S
        • et al.
        Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics.
        Am J Emerg Med. 2014; 32: 1195-1199
        • Harvard Drug Group
        Rugby Laboratories.
        Safety data sheet exemption. April 2015; (Available from:)
      1. Forrest Health. Florastor. Available from: http://www.forresthealth.com/florastor-biocodex.html. Accessed September 4, 2018.

        • Baron EJ
        • Tenover FC
        The emerging threat of Clostridium difficile infection: new insights into diagnosis and disease management. Cepheid C. difficile monograph.
        2018 (Available from:)
        www.cepheid.com
        Date accessed: September 4, 2018

      Linked Article

      • Re: Saltzman et al study on probiotics and prevention of CDI-the importance of probiotic strain specificity
        American Journal of Infection ControlVol. 48Issue 3
        • Preview
          In a recent retrospective study by Saltzman et al published in this journal, it was reported probiotics were found to be ineffective for the primary prevention of Clostridium. difficile infections (CDI).1 The authors gathered a 10% sample of patients who had been given antibiotics at high risk for CDI who either taken one of 2 types of probiotics (Lactobacillus acidophilus or Saccharomyces boulardii) or no probiotics. They did report the sample of patients who took any probiotic were significantly older and had been given more multiple antibiotics than the control group.
        • Full-Text
        • PDF